Halozyme to Present at Upcoming Investor Conferences

Rhea-AI Summary

Halozyme Therapeutics (NASDAQ: HALO) has announced its participation in three upcoming investor conferences in September 2024. The company's leadership, including Dr. Helen Torley, President and CEO, and Tram Bui, VP of Investor Relations, will be presenting and hosting investor meetings at these events.

The conferences include the 2024 Wells Fargo Healthcare Conference in Boston on September 4, the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 5, and the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 10. Presentations at Wells Fargo and H.C. Wainwright will be in a fireside chat format, while the Morgan Stanley event will feature 1x1 meetings only.

Live audio webcasts of the presentations will be available on Halozyme's website, with replays accessible for 90 days after each conference.

SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Investor Relations and Corporate Communications, are scheduled to present and host investor meetings at the following investor conferences.  

Details of the presentations are as follow:

Event:				2024 Wells Fargo Healthcare Conference
Format:				Fireside Chat and 1x1 Meetings
Presentation Date:				Wednesday, September 4, 2024
Presentation Time:				12:00 p.m. PT / 3:00 p.m. ET
Location:				Boston, MA

Event:					Morgan Stanley 22nd Annual Global Healthcare Conference
Format:					1x1 Meetings
Date:					Thursday, September 5, 2024
Location:					New York, NY

Event:	H.C. Wainwright 26th Annual Global Investment Conference
Format:	Fireside Chat and 1x1 Meetings
Presentation Date:	Tuesday, September 10, 2024
Presentation Time:	7:00 a.m. PT / 10:00 a.m. ET
Location:	New York, NY

A live audio webcast of the presentations will be available in the Investor Relations section of the Company's website. Replays of the audio webcast will be available for 90 days following the conference.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE^® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in eight commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE^® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex^® and XYOSTED^®, partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals.

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.

Contacts:

Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com 

Samantha Gaspar
Teneo
212-886-9356
samantha.gaspar@teneo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-present-at-upcoming-investor-conferences-302232554.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

When is Halozyme (HALO) presenting at the Wells Fargo Healthcare Conference in 2024?

Halozyme (HALO) is scheduled to present at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 12:00 p.m. PT / 3:00 p.m. ET in Boston, MA.

Which investor conferences is Halozyme (HALO) attending in September 2024?

Halozyme (HALO) is attending three investor conferences in September 2024: the Wells Fargo Healthcare Conference, the Morgan Stanley 22nd Annual Global Healthcare Conference, and the H.C. Wainwright 26th Annual Global Investment Conference.

Who will be representing Halozyme (HALO) at the upcoming investor conferences?

Dr. Helen Torley, President and CEO, and Tram Bui, VP of Investor Relations and Corporate Communications, will be representing Halozyme (HALO) at the upcoming investor conferences.

Where can investors access the live audio webcasts of Halozyme's (HALO) presentations?

Investors can access the live audio webcasts of Halozyme's (HALO) presentations in the Investor Relations section of the company's website.

How long will the replays of Halozyme's (HALO) presentation webcasts be available?

Replays of Halozyme's (HALO) presentation webcasts will be available for 90 days following each conference.